What are the recommended cervical cancer screening guidelines, including age to start, screening intervals, methods, and special considerations for high‑risk women?

Cervical Cancer Screening Guidelines

When to Start Screening

Begin cervical cancer screening at age 21 years for all individuals with a cervix, regardless of sexual history, age at first intercourse, or HPV vaccination status. 1

• Women younger than 21 years should never be screened, as cervical cancer is exceedingly rare in this age group and screening causes substantial harm through unnecessary procedures, psychological distress, and potential obstetric complications from overtreatment of lesions that would spontaneously regress 1, 2

Screening Strategies by Age Group

Ages 21-29 Years

Perform cervical cytology (Pap test) alone every 3 years—this is the only recommended approach for this age group. 1, 2

• HPV testing (either alone or as cotesting with cytology) is explicitly not recommended in women under 30 years because transient HPV infections are extremely common and resolve spontaneously, leading to unnecessary colposcopies and overtreatment 1
• The 2020 American Cancer Society guideline now recommends starting at age 25 years with primary HPV testing every 5 years as the preferred strategy, though cotesting every 5 years or cytology alone every 3 years remain acceptable during the transition period 1, 3
• Annual screening is never appropriate at any age—it provides minimal additional benefit while dramatically increasing false-positives and unnecessary procedures 1, 2

Ages 30-65 Years

The preferred approach is cotesting (HPV testing plus cytology) every 5 years, though three strategies are considered acceptable: 1, 2

1. Primary HPV testing alone every 5 years (preferred by the 2020 ACS guideline) 1, 3
2. Cotesting (HPV + cytology) every 5 years (preferred by ACOG and NCCN) 1, 3
3. Cytology alone every 3 years (acceptable but less preferred) 1, 2

• A negative HPV test or negative cotest provides extremely low 5-year risk of high-grade lesions (0.27% for negative cotesting, 0.34% for negative HPV alone), justifying the 5-year interval 1, 3
• The ACS notes that cotesting and cytology-alone will be phased out as the United States transitions to primary HPV testing 1, 3

When to Stop Screening

Women should discontinue screening after age 65 years only if ALL of the following criteria are met: 1, 4, 2

• Adequate prior screening: Either 3 consecutive negative cytology tests OR 2 consecutive negative HPV tests OR 2 consecutive negative cotests within the past 10 years 1, 4
• Most recent test within 5 years 1, 4
• No history of CIN 2/3, adenocarcinoma in situ, or cervical cancer in the past 20-25 years 1, 4, 5
• No high-risk conditions (HIV, immunosuppression, in utero DES exposure) 1, 5

Updated 2026 ACS Exit Criteria

The American Cancer Society now recommends HPV testing at ages 60 and 65 years, with the last HPV test at age 65 or older as a requisite to exit screening. 6

• This change addresses the high rates of cervical cancer in women over 65 and poor implementation of previous exit criteria 6
• If self-collected vaginal specimens are used for HPV testing, follow the 3-year testing interval 6

Special Populations Requiring Modified Screening

High-Risk Women Who Must Continue Screening Beyond Age 65

Women with a history of CIN 2/3, adenocarcinoma in situ, or cervical cancer must continue screening for at least 20-25 years after treatment, even if this extends well past age 65 years. 1, 4, 5

• Approximately 20% of cervical cancers are diagnosed after age 65, predominantly in unscreened or inadequately screened women 5
• Women who cannot document adequate prior screening must continue screening until criteria are met 4, 5

Immunocompromised Women

HIV-positive women and other immunocompromised individuals (organ transplant recipients, chronic corticosteroid users, chemotherapy patients) require more intensive, often annual screening, regardless of age. 1, 4, 3

• Standard screening intervals do not apply to these high-risk populations 4, 3

Post-Hysterectomy

Women who have had a total hysterectomy with removal of the cervix for benign reasons should NOT be screened. 1, 2

• Continue screening if the hysterectomy was performed for CIN 2/3 or cervical cancer—these women require annual vaginal cytology for at least 20-25 years post-treatment 4, 5
• Women who underwent subtotal hysterectomy (cervix retained) should follow standard screening recommendations 1

HPV Vaccination Status

Screening recommendations do NOT change based on HPV vaccination status—all vaccinated women must follow the same age-based screening guidelines. 1, 4

• Current vaccines do not cover all oncogenic HPV types, so screening remains essential 1, 4, 3

Self-Collection for HPV Testing (2026 Update)

Self-collected vaginal specimens for HPV testing are now acceptable for average-risk individuals aged 25-65 years, though clinician-collected cervical specimens remain preferred. 6

• When using self-collected specimens, repeat testing every 3 years after a negative result (not 5 years as with clinician-collected samples) 6
• This applies only to FDA-approved combinations of collection devices and HPV assays 6
• Self-collection can overcome barriers to screening but requires extra follow-up steps for HPV-positive results 6

Common Pitfalls to Avoid

Critical Errors in Practice

• Never discontinue screening at age 65 without verifying adequate prior screening through medical records review—patient self-report is insufficient 4, 5
• Never screen women under age 21, regardless of sexual activity—this is a Grade D recommendation because harms outweigh benefits 1, 3, 2
• Never perform annual screening at any age—more frequent testing provides minimal benefit while increasing false-positives and overtreatment 1, 3
• Never use HPV testing (alone or cotesting) in women under 30—high rates of transient infections lead to excessive false-positives 1, 3
• Never stop screening in women with prior CIN 2/3 until 20-25 years have elapsed since treatment, regardless of current age 4, 5
• Never screen women after total hysterectomy for benign disease—the yield is extremely low and represents unnecessary healthcare utilization 4, 5

Documentation Requirements

• Always verify screening history through pathology reports and medical records, not patient recall 4, 5
• Confirm that women over 65 meet ALL exit criteria before discontinuing screening 4, 5
• Document the indication for testing (screening vs. surveillance vs. diagnostic workup) to guide appropriate management 7

Management of Abnormal Results

Immediate Colposcopy Indications

The following results mandate immediate colposcopic evaluation: 3

• Squamous cell carcinoma (84% risk of HSIL/cancer) 3
• HSIL with or without HPV positivity (49-71% risk) 3
• ASC-H (atypical squamous cells—cannot exclude HSIL) (12-45% risk) 3
• Atypical glandular cells (AGC) (2-45% risk) 3
• HPV-positive LSIL (19% risk) 3
• HPV-positive ASC-US (18% risk) 3

Follow-Up Intervals for Lower-Risk Abnormalities

• HPV-positive with negative cytology: Repeat testing in 6-12 months (10% risk of HSIL/cancer) 3
• ASC-US without HPV testing or HPV-negative: Repeat testing in 6-12 months (1-7% risk) 3
• HPV-negative with ASC-US: Repeat testing in 3 years (1.1% risk) 3
• Negative cotest (HPV-negative with negative cytology): Repeat testing in 5 years (0.27% risk—lowest risk category) 3